Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good afternoon. I'm Doug Onsi, the President and CEO of Leap Therapeutics, and it's a pleasure to be able to start a year here in the virtual grand ballroom at the JPMorgan 38th Annual Healthcare Conference. I'm very excited to be able to give you an update on Leap Therapeutics to introduce those of you who are new to Leap or our company, an update on DKN-01, our clinical development program and our plans for a very big year ahead in 2021.
If you turn to Slide 2, you'll see that my presentation will include forward-looking statements.
Moving -- advancing to Slide 3. So Leap Therapeutics is an oncology drug development company that's focused on developing our DKN-01 monoclonal antibody. DKN-01 targets DKK1, which is a protein produced by cancer cells that modulates important immune signaling pathways in tumor cell signaling pathways and plays a key role in maintaining an immunosuppressive tumor microenvironment.
1 year ago, we announced a strategic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |